Two synthetic derivatives of the natural flavonoid fisetin — SR29384 and SR31133 — demonstrated superior senolytic activity compared to their parent compound in mouse aging models. Developed via phenotypic drug discovery and validated through transcriptomics, machine learning, and molecular docking, both compounds selectively induced apoptosis in multiple senescent cell types, reduced tissue senescence burden, and improved healthspan-associated parameters. Mechanistic analysis implicated PARP1, CDK2, and possibly BCL-xL as key targets — the same anti-apoptotic pathway family exploited by the established senolytic combination dasatinib plus quercetin.
Fisetin has been the most clinically tractable natural senolytic to date, with human trials underway, yet its poor bioavailability and modest efficacy have consistently blunted enthusiasm. SR29384 and SR31133 appear engineered specifically to overcome those pharmacokinetic liabilities, which makes this more than routine medicinal chemistry iteration. The BCL-xL targeting angle is notable: navitoclax, a potent BCL-xL inhibitor, clears senescent cells effectively but causes dose-limiting platelet toxicity in humans. Flavonoid-based BCL-xL modulators might offer a safer route to the same mechanism. The critical caveat is that all efficacy data come from mouse models — a setting where senolytics have repeatedly impressed before failing to translate cleanly to humans. No human pharmacokinetic, safety, or efficacy data are presented. Still, the integrative discovery platform and dual-compound validation represent a methodologically rigorous step forward. Adults following senolytic research should watch for Phase I safety data before drawing practical conclusions.